<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35263451</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2567</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>166</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunology</Title>
          <ISOAbbreviation>Immunology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CTLA4Ig/VISTAIg combination therapy selectively induces CD4<sup>+</sup> T cell-mediated immune tolerance by targeting the SOCS1 signaling pathway in porcine islet xenotransplantation.</ArticleTitle>
        <Pagination>
          <StartPage>169</StartPage>
          <EndPage>184</EndPage>
          <MedlinePgn>169-184</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.13463</ELocationID>
        <Abstract>
          <AbstractText>T cell inhibitory receptors can regulate the proliferation or function of T cells by binding to their ligands and present a unique opportunity to manage destructive immune responses during porcine islet xenotransplantation. We applied ex vivo porcine islet xenotransplantation and in vitro mixed lymphocyte-islet reaction models to assess immune checkpoint receptor expression profiles in recipient T cells, investigated whether CTLA4 or VISTA immunoglobulin (Ig) combination therapy alone could suppress porcine islet xenograft rejection and further analyzed its potential immune tolerance mechanism. Recipient T cells expressed moderate to high levels of CTLA4, PD-1, TIGIT and VISTA, and the frequency of CTLA4<sup>+</sup> CD4<sup>+</sup> , TIGIT<sup>+</sup> CD4<sup>+</sup> , VISTA<sup>+</sup> CD4<sup>+</sup> and VISTA<sup>+</sup> CD8<sup>+</sup> T cells was positively correlated with porcine islet xenograft survival time in xenotransplant recipients. Combined treatment with CTLA4Ig and VISTAIg selectively inhibited recipient CD4<sup>+</sup> T cell hyper-responsiveness and proinflammatory cytokine production and significantly delayed xenograft rejection. SOCS1 deficiency in CD4<sup>+</sup> T cells stimulated by xenogeneic islets facilitated hyper-responsiveness and abolished the suppressive effect of combination therapy on recipient T cell-mediated porcine islet damage in vivo and in vitro. Further mechanistic studies revealed that combined treatment significantly induced SOCS1 expression and inhibited the Jak-STAT signalling pathway in wild-type recipient CD4<sup>+</sup> T cells stimulated by xenogeneic islets, whereas SOCS1 deficiency resulted in Jak-STAT signalling pathway activation in recipient CD4<sup>+</sup> T cells. We demonstrated a major role for CTLA4 and VISTA as key targets in CD4<sup>+</sup> T cell hyper-responsiveness and porcine islet xenograft rejection. The selective inhibition of CD4<sup>+</sup> T cell immunity by CTLA4Ig/VISTAIg is based on SOCS1-dependent signalling.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Xue</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Life Science, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Qiying</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Animal Center, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Weihua</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Institutes of Neuroscience, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xinying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ruoyuan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Caihua</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Sirong</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-8576-0847</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Immunology</MedlineTA>
        <NlmUniqueID>0374672</NlmUniqueID>
        <ISSNLinking>0019-2805</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C108944">SOCS1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071222">Suppressor of Cytokine Signaling 1 Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006085" MajorTopicYN="N">Graft Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016381" MajorTopicYN="Y">Islets of Langerhans Transplantation</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071222" MajorTopicYN="N">Suppressor of Cytokine Signaling 1 Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">combination therapy</Keyword>
        <Keyword MajorTopicYN="N">immune checkpoint</Keyword>
        <Keyword MajorTopicYN="N">immune tolerance</Keyword>
        <Keyword MajorTopicYN="N">porcine islet xenotransplantation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>17</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35263451</ArticleId>
        <ArticleId IdType="doi">10.1111/imm.13463</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Yang YG, Sykes M. Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol. 2007;7:519-31.</Citation>
        </Reference>
        <Reference>
          <Citation>Cooper DKC, Gaston R, Eckhoff D, Ladowski J, Yamamoto T, Wang L, et al. Xenotransplantation-the current status and prospects. Br Med Bull. 2018;125:5-14.</Citation>
        </Reference>
        <Reference>
          <Citation>Reichart B, Niemann H, Chavakis T, Denner J, Jaeckel E, Ludwig B, et al. Xenotransplantation of porcine islet cells as a potential option for the treatment of type 1 diabetes in the future. Horm Metab Res. 2015;47:31-5.</Citation>
        </Reference>
        <Reference>
          <Citation>Hering BJ, Wijkstrom M, Graham ML, Hårdstedt M, Aasheim TC, Jie T, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates[J]. Nat Med. 2006;12:301-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med. 2006;12:304-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Scalea J, Hanecamp I, Robson SC, Yamada K. T-cell mediated immunological barriers to xenotransplantation. Xenotransplantation. 2012;19:23-30.</Citation>
        </Reference>
        <Reference>
          <Citation>Friedman T, Smith R, Colvin R, Iacomini J. A critical role for human CD4T-cells in rejection of porcine islet cell xenografts. Diabetes. 1999;48:2340-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Yi S, Feng X, Hawthorne WJ, Patel AT, Walters SN, O'Connell PJ. CD4+ T cells initiate pancreatic islet xenograft rejection via an interferon-gamma-dependent recruitment of macrophages and natural killer cells. Transplantation. 2002;73:437-46.</Citation>
        </Reference>
        <Reference>
          <Citation>Kirchhof N, Shibata S, Wijkstrom M, Kulick DM, Salerno CT, Clemmings SM, et al. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation. 2004;11:396-407.</Citation>
        </Reference>
        <Reference>
          <Citation>Lehnert AM, Mottram PL, Han W, Walters SN, Patel AT, Hawthorne WJ, et al. Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice. Transpl Immunol. 2001;9:51-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42.</Citation>
        </Reference>
        <Reference>
          <Citation>Mardomi A, Mohammadi N, Khosroshahi HT, Abediankenari S. An update on potentials and promises of T cell co-signaling molecules in transplantation. J Cell Physiol. 2020;235:4183-97.</Citation>
        </Reference>
        <Reference>
          <Citation>Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov. 2011;10:655-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Schwarz C, Mahr B, Muckenhuber M, Wekerle T. Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results. Expert Rev Clin Immunol. 2018;14:583-92.</Citation>
        </Reference>
        <Reference>
          <Citation>El Khatib MM, Sakuma T, Tonne JM, Mohamed MS, Holditch SJ, Lu B, et al. Beta-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. Gene Ther. 2015;22:430-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes. 2005;54:443-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Yoon IH, Chung H, Kim HJ, Nam HY, Shin JS, Kim YH, et al. Peri-graft porcine-specific CD4(+) FoxP3(+) regulatory T cells by CD40-CD154 blockade prevented the rejection of porcine islet graft in diabetic mice. Xenotransplantation. 2019;26:e12533.</Citation>
        </Reference>
        <Reference>
          <Citation>Thompson P, Cardona K, Russell M, Badell IR, Shaffer V, Korbutt G, et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant. 2011;11:947-57.</Citation>
        </Reference>
        <Reference>
          <Citation>Meggyes M, Szanto J, Lajko A, Farkas B, Varnagy A, Tamas P, et al. The possible role of CD8+/Valpha7.2+/CD161++ T (MAIT) and CD8+/Valpha7.2+/ CD161(lo) T (MAIT-like) cells in the pathogenesis of early-onset pre-eclampsia. Am J Reprod Immunol. 2018;79:e12805.</Citation>
        </Reference>
        <Reference>
          <Citation>Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290:72-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016;57:54-60.</Citation>
        </Reference>
        <Reference>
          <Citation>Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, et al. Combination anti-CTLA-4 plus anti-PD-1checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci USA. 2019;116(45):22699-22709.</Citation>
        </Reference>
        <Reference>
          <Citation>Rabinovitch A, Fuller L, Mintz D, Severyn W, Noel J, Flaa C, et al. Responses of canine lymphocytes to allogeneic and autologous Islets of Langerhans in mixed cell cultures. J Clin Invest. 1981;67:1507-16.</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999;98:597-608.</Citation>
        </Reference>
        <Reference>
          <Citation>Marine JC, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 1999;98:609-16.</Citation>
        </Reference>
        <Reference>
          <Citation>Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol. 2003;4:1169-76.</Citation>
        </Reference>
        <Reference>
          <Citation>Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med. 2006;203:1391-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Takahashi R, Nakatsukasa H, Shiozawa S, Yoshimura A. SOCS1 is a key molecule that prevents regulatory T cell plasticity under inflammatory conditions. J Immunol. 2017;199:149-58.</Citation>
        </Reference>
        <Reference>
          <Citation>Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-94.</Citation>
        </Reference>
        <Reference>
          <Citation>Finger EB, Bluestone JA. When ligand becomes receptor-tolerance via B7 signaling on DCs. Nat Immunol. 2002;3:1056-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, et al. Immunoregulatory functions of VISTA. Immunol Rev. 2017;276:66-79.</Citation>
        </Reference>
        <Reference>
          <Citation>Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35:238-255.e6.</Citation>
        </Reference>
        <Reference>
          <Citation>Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-4.</Citation>
        </Reference>
        <Reference>
          <Citation>Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-21.</Citation>
        </Reference>
        <Reference>
          <Citation>Cornish AL, Chong MM, Davey GM, Darwiche R, Nicola NA, Hilton DJ, et al. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. J Biol Chem. 2003;278:22755-61.</Citation>
        </Reference>
        <Reference>
          <Citation>Ramanathan S, Gagnon J, Leblanc C, Rottapel R, Ilangumaran S. Suppressor of cytokine signaling 1 stringently regulates distinct functions of IL-7 and IL-15 in vivo during T lymphocyte development and homeostasis. J Immunol. 2006;176:4029-41.</Citation>
        </Reference>
        <Reference>
          <Citation>Jameson SC. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol. 2002;2:547-56.</Citation>
        </Reference>
        <Reference>
          <Citation>Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol. 2011;12:478-84.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
